Skip to main content
Raymond Joseph, MD, Gastroenterology, Gladwyne, PA

Raymond Edward Joseph MD

Gastroenterology•Gladwyne, PA

Inflammatory Bowel Disease

Physician

Join to View Full Profile

  • 1618 Winston RdGladwyne, PA 19035

  • Phone+1 610-896-1773

  • Fax+1 610-896-1773

Dr. Joseph is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Joseph's Full ProfileAlready have an account?

Summary

  • Profile:
    Board certified in Internal Medicine, Gastroenterology, Hepatology & Board eligible in Anatomical Pathology (Ford Foundation Fellow in hepatic biopsy pathology & GI surg. path)
    Latest title – Associate Vice President at Ferring Global Pharmaceutical Company. Greater than 15 years’ experience leading global drug development progressing through Phase I-III clinical development to launch to successful commercialization and Phase-IV.
    Marked experience with regulatory meetings with FDA, MAA, Health Canada, etc.
    Co-Chair of (2) global drug safety teams. Co-chair with VP of Pharmacovigilance - Lialda™/Mesavant™/MesavantXL™; Pentasa® Core Team in charge of clinical data use in all promotional publications and medical global safety lead. Member of ‘Open session’ of External Safety Monitoring Board (Merck) orchestrating the compilation of ‘data packages’ for adjudication of selected adverse experiences (MIs, CVAs and peptic ulcer disease).
    Leadership roles in global inflammatory diseases especially ulcerative colitis and Crohn’s disease. Evaluated Elobixibat (A3309) P-I &II. Elobixibat is an ileal bile transport inhibitor that increases bile acid delivery to the colon with effects on the inhibition of BA absorption with reduced activation of the Farnesoid X Receptor leading to increased bile acid synthesis culminating in increased bile acids in the bowel, and designed the global P-III clinical trials.
    Empowered global, highly matrixed clinical teams that led to commercialization of: Lialda, Mesavant®, Mesavant XL®, Quintasa, PrepoPic & ClenPiQ. Additionally, a team member for FDA approval of - EMEND® and Zetia® (contributed to Integrated Summary of Safety).
    Investigator in global somatostatin for variceal bleeding trial, several GI P-III and IV studies and others in sub-investigator roles

    Key Areas of Expertise Include:

    •    Three years’ experience at FDA Senior Specialist at both CDER and CBER) Prepared analyses for

Education & Training

  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Gastroenterology, 1977 - 1979
  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1975 - 1977
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pathology-Anatomic and Clinical, 1973 - 1975
  • Ohio State University Hospital
    Ohio State University HospitalInternship, Transitional Year, 1972 - 1973
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 1972

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1976 - 2026

Awards, Honors, & Recognition

  • Team Leadership Award PrepoPik Global Team, 2013
  • True Grit Award Ferring Pharmaceuticals, 2011
  • Recognizing Excellence Impact Award R&D Leadership Team, 2006

Publications & Presentations

PubMed

Journal Articles

  • A Dual-Action, Low-Volume Bowel Cleanser Administered the Day Before Colonoscopy: Results from the SEE CLEAR II Study  
    Katz P, Rex D, Epstein M, Grandhi N, Vanner S, Hookey L, Alderfer V, Joseph R, American Journal of Gastroenterology, 1/1/2013
  • Expanded Applications: The Potential usage of Mesalamine in Diverticular Disease  
    Tursi, A., Joseph, R.E., Streck, P., Dig Dis Sci, 1/1/2011
  • MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis  
    Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, Karlstadt RG, Diebold R, and Joseph R, Gastroenterol Hepatol (N Y), 1/1/2009

Books/Book Chapters

  • Progress with Domperidone, A Gastro kinetic and Antiemetic Agent: Royal Society of Medicine International Congress and Symposium Series No. 36 
    Chapter: Domperidone in Patients with Postprandial Upper Gastrointestinal Distress 
    Gordon SJ and Joseph REAcademic Press Inc. (London) Ltd., and the Royal Society of Medicine, London1981

Abstracts/Posters

  • Serum magnesium levels are not affected by renal function in patients receiving split-dose, low-volume sodium picosulfate and magnesium citrate bowel preparation.
    Bertiger G, Jones E, Dahdal D, Joseph RE, 2014 Digestive Diseases Week Annual Meeting, Chicago, IL, 1/4/2014
  • Serum magnesium levels are not affected by renal function in patients receiving split-dose low-volume sodium picosulfate and magnesium citrate bowel preparation
    Bertiger G, Jones E, Dahdal D, Joseph RE, Gastrointest Endosc, 1/1/2014
  • Serum magnesium levels are not affected by renal function in patients receiving split-dose low-volume sodium picosulfate and magnesium citrate bowel preparation.
    Bertiger G, Jones E, Dahdal D, Joseph RE, Gastrointest Endosc, 1/1/2014

Lectures

  • Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose mesalazine formulation can change to once-or twice-daily MMX�mesalazine and... 
    Montreal, Canada - 1/1/2008
  • Advances In Ulcerative Colitis 
    Phoenix, AZ; Miami, FL - 1/25/2006
  • TARGET study (lumiracoxib) review and perspective with CLASS and VIGOR. 
    Blue Bell, PA - 1/27/2004

Other

  • Once-Or Twice-Daily MMX Mesalazine (2.4g/Day) Is Effective for The Maintenance Of Remission of Mild-To-Moderate Ulcerative Colitis Regardless of The Mesalazine Dose Or... 
    Colombel JF, Diebold R, Karlstadt R, Barrett K, Joseph R, Shire Pharmaceuticals Inc., Vol. 2, No. 1, pp. 17-17
    Basingstoke, United Kingdom - 1/1/2008
  • MMX Mesalazine is an effective treatment for active, mild-to-moderate UC regardless of prior 5-ASA use: a pooled analysis of two placebo-controlled, Phase III Trials, ... 
    Kamm M, Lichtenstein G, Sandborn W, Barrett K, Joseph R, Shire Pharmaceuticals Inc., Vol. 1, No. 1, Pages 18-18
    Wayne, PA - 1/1/2007
  • Biologic License Application (BLA) Medical Officer's Review (Remicade®) 
    Joseph RE, Food and Drug Administration
    Rockville, MD - 1/26/2003

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Raymond Joseph, Dr. Raymond Joseph, MD, Dr. R Joseph, Dr. Raymond Edward Joseph